Rocket Pharmaceuticals, Inc. — FY 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; this is an annual report, not a standalone fourth-quarter filing. Rocket is a clinical-stage gene-therapy company focused on rare diseases and had no approved products or product-sales revenue.
Financial performance and position
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $58.6 million | $53.3 million |
| General and administrative expense | $17.5 million | $17.9 million |
| Total operating expenses | $76.2 million | $71.2 million |
| Net loss | $77.3 million | $74.5 million |
| Net loss per share | $1.58 | $1.89 |
| Cash used in operating activities | $64.7 million | $53.8 million |
| Cash used in investing activities | $39.0 million | $5.3 million |
| Cash provided by financing activities | $177.8 million | $153.5 million |
At year-end, cash and cash equivalents were $185.4 million and investments were $118.7 million, totaling $304.1 million. Current assets were $307.8 million, current liabilities $18.3 million, and total liabilities $64.8 million. The company reported $52.0 million principal on its unsecured 5.75% convertible notes due August 2021, carried at $45.0 million net of discount. No operating margin is meaningful given the absence of revenue.
Changes versus FY 2018
- Net loss increased $2.8 million, while operating expenses rose $5.0 million. R&D expense increased $5.4 million, largely from clinical-trial costs, higher R&D compensation, and research agreements.
- R&D expense included a lower licensing burden than in 2018, when a $7.0 million REGENXBIO license fee was incurred. G&A declined slightly year over year, but excluding $5.3 million of one-time reverse-merger costs in 2018, G&A increased about $5.0 million, primarily due to stock-based compensation and staffing.
- Operating cash use rose $10.9 million. Investing cash use increased mainly because of $23.3 million of property and equipment purchases, principally Cranbury facility construction.
- Net loss per share improved to $1.58 from $1.89, alongside a higher weighted-average share count following equity financings.
Pipeline, outlook, and material developments
- Fanconi anemia (RP-L102): Phase 2 registration-enabling study began dosing its first patient in December 2019; planned enrollment is 10. FDA alignment on trial design and the primary endpoint was reported. Preliminary results from two Process B patients showed early engraftment signals and no reported treatment-related safety or tolerability issues at that time.
- LAD-I (RP-L201): Phase 1/2 study dosed its first U.S. patient in 2019, with planned global enrollment of nine. Early data through three months showed VCN of 1.5 in myeloid cells and 45% CD18 expression; no related safety or tolerability issues had been identified. CIRM awarded up to $6.5 million; $1.2 million had been received in 2019.
- PKD (RP-L301): IND cleared in 2019 and Phase 1 enrollment was ongoing; preliminary data were anticipated in the second half of 2020.
- Danon disease (RP-A501): FDA-cleared clinical program with Fast Track designation; three patients had been dosed. Further enrollment and clinical data readouts were anticipated in the second half of 2020.
- IMO (RP-L401): Preclinical program; the company intended to file an IND and begin a trial in the second half of 2020.
- Management expected year-end cash, cash equivalents, and investments to fund operating and capital requirements into 2022. It expected R&D and G&A spending to rise as trials and programs advanced, and forecast up to $30 million in non-recurring 2020 Cranbury facility costs. These are management expectations, not guarantees.
- In April and December 2019, public offerings generated net proceeds of approximately $86.1 million and $91.7 million, respectively. After year-end, in February 2020, Rocket exchanged about $39.4 million of notes due 2021 for the same principal amount of 6.25% notes due 2022; approximately $12.7 million of the 2021 notes remained outstanding. These subsequent events were not year-end 2019 balances.
Risks, contingencies, and unusual items
- Rocket has recurring losses, no product revenue, and expects substantial future R&D spending; further financing may be needed if development costs, timelines, or commercial plans exceed expectations.
- Clinical outcomes, patient enrollment, regulatory review, long-term gene-therapy safety, and manufacturing execution are uncertain. All programs remain investigational and early clinical findings may not predict later results.
- The company depended on third-party manufacturers and had no commercial manufacturing experience. The Cranbury facility buildout, regulatory readiness, cost, and execution are important risks.
- The filing identified COVID-19 as a potential risk to staff, clinical-trial resources, suppliers, and the supply chain; the extent of any impact was uncertain at filing.
- Convertible notes carry interest and potential dilution on conversion. Additional equity financing could dilute existing holders. The filing reported no material litigation expected to adversely affect the company.
- FY 2019 financial statements reflect adoption of lease accounting; Rocket recorded $2.4 million of operating lease liabilities at year-end, while the Cranbury lease had not yet commenced for balance-sheet recognition.
Important facts for investors to verify
- Current cash, investment balances, quarterly cash burn, and whether the stated runway into 2022 remains achievable.
- Updated enrollment, safety, efficacy, and regulatory milestones for RP-L102, RP-L201, RP-L301, and RP-A501; compare new data with the preliminary results described in this filing.
- Cranbury facility completion, capital spending, regulatory qualification, and effect on manufacturing capacity and costs.
- Outstanding note principal, terms and potential dilution of the 2022 notes, and any further refinancing or financing needs.
- Whether COVID-19 or other operational disruptions affected trials, suppliers, timelines, or costs after the filing date.